Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$11.56 USD

11.56
944,617

+0.23 (2.03%)

Updated Nov 5, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Benjamin Rains headshot

How to Find Cheap Buy-Ranked Stocks Trading Under $10

by Benjamin Rains

Check out 5 stocks of the roughly 40 highly-ranked 'cheap' stocks trading under $10 a share that made it through today's screen...

Amicus' (FOLD) Shares Rise on Q3 Earnings & Revenue Beat

by Zacks Equity Research

Amicus (FOLD) reports a narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

Company News For Nov 12, 2019

by Zacks Equity Research

Companies In The News Are: QRTEA, FOLD, NKTR, WBA, KKR.

Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25.00% and 1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Cronos (CRON) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2019 results.

CannTrust (CTST) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.

What's in Store for Cumberland Pharma (CPIX) in Q3 Earnings?

by Zacks Equity Research

Cumberland Pharmaceuticals' (CPIX) third-quarter results are expected to reflect solid sales growth.

Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.

PCTEL (PCTI) Gears Up for Q3 Earnings: What's in Store?

by Zacks Equity Research

PCTEL's (PCTI) third-quarter performance is likely have benefited from the demand for 5G scanning receivers and Industrial IoT antenna project wins.

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the third quarter driven by clinical studies on its lead pipeline candidate, Zygel.

Amicus Therapeutics (FOLD) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Amicus Therapeutics (FOLD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CenturyLink (CTL) Gears Up for Q3 Earnings: What's in Store?

by Zacks Equity Research

CenturyLink's (CTL) third-quarter performance is likely to have benefited from its focus on improving revenues while continuing deleveraging and cost-transformation initiatives.

Why Is Amicus Therapeutics (FOLD) Down 18.9% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View

by Zacks Equity Research

Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.

Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 0.00% and 7.32%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Amicus Therapeutics (FOLD) Down 9.6% Since Last Earnings Report?

by Zacks Equity Research

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -25.81% and -9.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for Catalyst Pharma (CPRX) Q1 Earnings?

by Zacks Equity Research

Catalyst Pharma (CPRX) is expected to announce revenue results on its lead product, Firdapse, when it releases first-quarter 2019 earnings performance.

    Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Amicus Therapeutics (FOLD) Up 12.4% Since Last Earnings Report: Can It Continue?

    by Zacks Equity Research

    Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Amicus (FOLD) Reports Wider-than-Expected-Loss for 2018

    by Zacks Equity Research

    Amicus (FOLD) reports wider-than-expected loss in 2018, while revenues exceed estimates.

    What's in Store for Universal Health (UHS) Q4 Earnings?

    by Zacks Equity Research

    Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.